scholarly journals HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Anna Di Benedetto ◽  
Marcella Mottolese ◽  
Francesca Sperati ◽  
Cristiana Ercolani ◽  
Luigi Di Lauro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Hormone Receptors ◽  
Male Breast ◽  
Survival Outcomes

Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016

2018 ◽  
Vol 67 (3) ◽  
pp. 699-705
Author(s):  
Weigang Wang ◽  
Xiaoqin Xu ◽  
Baoguo Tian ◽  
Yan Wang ◽  
Lili Du ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Features ◽  
Male Breast Cancer ◽  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
Cox Proportional Hazards ◽  
Male Breast ◽  
Shanxi Province ◽  
Smoking History ◽  
Large Sample Size

This study aims to understand the clinical features, treatment, and prognosis of patients with male breast cancer (MBC) in Shanxi province of China from 2007 to 2016. Data for 77 patients with MBC were collected for analysis. Immunohistochemistry, pathological results, and other data such as demographic characteristics (age, marital status, smoking history, drinking history, and family history of cancer) as well as clinical data were investigated by retrieving information from the patients’ medical records. A total of 12,404 patients were diagnosed with breast cancer between 2007 and 2016, and 77 were patients with MBC among them. The median diagnosis age of patients with MBC was 62 years (range, 24–84 years). The most common complaint was a painless lump in the breast, accounting for 68.8% of the patients, and the main pathological type in MBC was infiltrating ductal carcinoma (66.2%). In terms of hormone receptors, 80.5% (62/77) of patients with MBC were estrogen receptor positive, 75.3% (58/77) of patients were progesterone receptor positive, and only 6.5% (5/77) of patients were HER2 overexpressing. The multivariant Cox proportional hazards regression analysis showed that M stage is an independent prognostic factor (p=0.018, HR=18.791, 95% CI 1.663 to 212.6). The epidemiological and clinical features of Chinese MBC are similar to that of other countries. As the Chinese public have limited knowledge of MBC, it is necessary to increase awareness among them about it. Further research with a large sample size is required for better understanding of the risks associated with MBC.

Characteristics and survival of secondary male breast cancer: SEER database analysis.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13690-e13690
Author(s):  
John Khoury ◽  
Siddhartha Yadav ◽  
Tara Rangarajan ◽  
Dana Zakalik
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Hormone Receptors ◽  
Latency Period ◽  
Male Breast ◽  
Stage I ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Increased Risk

e13690 Background: Male breast cancer (MBC) is rare accounting for less than 0.5% of all cancer diagnoses in men. We used the term secondary male breast cancer (sMBC) to refer to ipsilateral and contralateral recurrences in addition to new primary MBC. Given its low incidence, data regarding the risk of developing sMBC and its characteristics are scarce. Methods: Multiple Primary Standardized Incidence Ratios (MP-SIR) session was conducted from the SEER*Stat software. We included all patients diagnosed with stage I,II and III MBC between 1990 to 2015 from the Surveillance Epidemiology and End Results (SEER) 18 registry. The standardized incidence ratio (SIR) was calculated as an estimate of the risk of a second primary malignancy based on the incidence in the general population. Descriptive statistics and Kaplan-Meier analysis were performed using SPSS software. Results: Among all 2321 men diagnosed with a first primary MBC during the study period, 28 patients had a subsequent diagnosis of MBC. The risk of sMBC was significantly elevated with SIR of 33.12 (95% CI, 22.18 – 47.56). The median latency period between the initial and subsequent diagnoses was 5.9 years. 82.1% of the patients were White, 14.3% Black and 3.6% Asian/Pacific Islander. Majority of the cases constituting 85.7% of sMBC were diagnosed in the contralateral breast. 67.8% of the sMBC remained hormone receptors status positive similar to the initial status of the primary diagnosis. 42.9% of the sMBC patients were diagnosed with stage I, 17.9% with stage II, 3.6% with stage III, 17.9% with stage IV and 17.9% of unknown stage. The median overall survival for sMBC was 96 months (95% CI, 11.3-180.6). We also found an increased risk of developing liver cancer (SIR: 2.16), prostate cancer (SIR: 1.29), thyroid cancer (SIR: 3.08) and acute myeloid leukemia (SIR: 2.4) in individuals after a diagnosis of MBC. Conclusions: Men diagnosed with breast cancer are at increased risk of sMBC in addition to other malignancies which require careful monitoring after completing initial treatment. Contralateral mammogram screening or prophylactic contralateral mastectomy can be considered based on patient’s preferences and values.

scholarly journals Clinicopathological characteristics and survival outcomes of male breast cancer according to race: A SEER population-based study

Oncotarget ◽  
2017 ◽  
Vol 8 (41) ◽  
pp. 69680-69690 ◽  
Author(s):  
He-Fen Sun ◽  
Yang Zhao ◽  
Shui-Ping Gao ◽  
Liang-Dong Li ◽  
Wen-Yan Fu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Population Based ◽  
Clinicopathological Characteristics ◽  
Male Breast ◽  
Survival Outcomes ◽  
Population Based Study

scholarly journals Poorer Survival Outcomes for Male Breast Cancer Compared with Female Breast Cancer May Be Attributable to In-Stage Migration

2010 ◽  
Vol 18 (7) ◽  
pp. 1837-1844 ◽  
Author(s):  
Jennifer L. Gnerlich ◽  
Anjali D. Deshpande ◽  
Donna B. Jeffe ◽  
Susmitha Seelam ◽  
Eric Kimbuende ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Survival Outcomes ◽  
Stage Migration ◽  
Female Breast

HORMONE RECEPTORS IN MALE BREAST CANCER

1984 ◽  
Vol 54 (3) ◽  
pp. 215-218 ◽  
Author(s):  
Ronald J. Mercer ◽  
Robert M. Bryan ◽  
Richard C. Bennett
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Hormone Receptors ◽  
Male Breast

scholarly journals Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer

2017 ◽  
Vol 232 (8) ◽  
pp. 2246-2252 ◽  
Author(s):  
Anna Di Benedetto ◽  
Marcella Mottolese ◽  
Francesca Sperati ◽  
Cristiana Ercolani ◽  
Luigi Di Lauro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Survival Outcomes

scholarly journals Survival Outcomes in Male Breast Cancer – A Single Institution Experience

2018 ◽  
Vol 3 (4) ◽  
pp. 71
Author(s):  
Nisha Hariharan
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Treatment Guidelines ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Survival Outcomes ◽  
Breast Cancers ◽  
Breast Cancer Patients

Introduction: Male breast cancer is an uncommon entity. Due to the scarce numbers, treatment protocolshave largely been extrapolated from available evidence for female breast cancers.Methods: We analysed the clinicopathological features and survival outcomes for male breast cancer patients treated at our institute between January 2010 and June 2016.Results: Of the 5534 women treated at our institute, we screened 40 male breast cancers of whom 33 had available follow up data and were included in the present analysis. Male breast cancer constituted 0.7% of all breast cancers. The median age was 60 years and the median tumor size was 3cm with 66% of patients having nodal disease at presentation. Invasive ductal carcinoma was the most common histology and 97% were hormone receptor positive. Most of the patients (87.8%) underwent an upfront modified radical mastectomy. With a median follow up of 36 months, 10 patients experienced recurrences all of which were distant metastasis (3 to the bone, 1 to the brain, and 6 had visceral metastasis). Of these, 7 patients succumbed to the disease. The 3-year overall survival was 78.7 %.Conclusion: Male breast cancer is a rare clinical entity and current treatment guidelines follow those for women. Due to the lack of awareness, men often present to clinics at an advanced stage. Social support targeted at improving awareness and access to treatment could improve outcomes in this cohort.  

Sign in / Sign up

Export Citation Format

Share Document